🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Alabama › Birmingham

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Birmingham, AL

Isang pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Birmingham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Nagre-recruitPhase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • Children's Hospital of Alabama, Birmingham
Hanggang edad 21 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07012044

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • University of Alabama at Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • University of Alabama at Birmingham Cancer Center, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Nagre-recruitPhase 3
  • Children's Hospital of Alabama, Birmingham
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Nagre-recruitPhase 2
  • University of Alabama - Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Nagre-recruitPhase 3
  • Children's Hospital of Alabama, Birmingham
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Nagre-recruitPhase 1/2
  • O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Nagre-recruitPhase 2/3
  • University of Alabama Birmingham, Birmingham
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06788756

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • University of Alabama at Birmingham, Birmingham
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

Nagre-recruit
  • University of Alabama at Birmingham, Division of Hematology and Oncology, Birmingham
Edad 60 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT06697600

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Nagre-recruitPhase 1
  • University of Alabama at Birmingham, Birmingham
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 4, 2026 · NCT07044544

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Nagre-recruitPhase 1
  • University of Alabama O'Neal Cancer Center, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 16, 2026 · NCT05143996

HPC Offered for PRESERVE Expansion

Nagre-recruitObservasyonal na pag-aaral
  • University of Alabama, Birmingham, Birmingham
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 28, 2025 · NCT07145411

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1/2
  • The Kirklin Clinic of UAB Hospital, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2025 · NCT03850574

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
  • University of Alabama - Birmingham, Birmingham
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 25, 2025 · NCT05237258

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Nagre-recruitPhase 1
  • University of Alabama at Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 15, 2024 · NCT06034275

Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod

Iba pang pag-aaral sa Birmingham

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.